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Abstract
 
Bone marrow–derived antigen-presenting cells (APCs) take up cell-associated antigens and
present them in the context of major histocompatibility complex (MHC) class I molecules to
 
CD8
 
1
 
 T cells in a process referred to as cross-priming. Cross-priming is essential for the induc-
tion of CD8
 
1
 
 T cell responses directed towards antigens not expressed in professional APCs.
Although in vitro experiments have shown that dendritic cells (DCs) and macrophages are ca-
pable of presenting exogenous antigens in association with MHC class I, the cross-presenting
cell in vivo has not been identified. We have isolated splenic DCs after in vivo priming with
 
ovalbumin-loaded 
 
b
 
2-microglobulin–deficient splenocytes and show that they indeed present
cell-associated antigens in the context of MHC class I molecules. This process is transporter as-
sociated with antigen presentation (TAP) dependent, suggesting an endosome to cytosol trans-
port. To determine whether a specific subset of splenic DCs is involved in this cross-presenta-
tion, we negatively and positively selected for CD8
 
2
 
 and CD8
 
1 
 
DCs. Only the CD8
 
1
 
, and not
 
the CD8
 
2
 
, DC subset demonstrates cross-priming ability. FACS
 
®
 
 studies after injection of sple-
nocytes loaded with fluorescent beads showed that 1 and 0.6% of the CD8
 
1 
 
and the CD8
 
2
 
 DC
subsets, respectively, had one or more associated beads. These results indicate that CD8
 
1 
 
DCs
play an important role in the generation of cytotoxic T lymphocyte responses specific for cell-
associated antigens.
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Introduction
 
Naive CD8
 
1
 
 T cells are stimulated to proliferate and to de-
velop into cytotoxic effector T cells after recognition of
short peptides associated with MHC class I molecules on
professional APCs. “Endogenous” cytosolic proteins are
generally the source of MHC class I–restricted antigens.
These proteins are degraded by the proteasome, and pep-
tides are transported to the endoplasmic reticulum by the
transporter associated with antigen presentation (TAP)
 
1
 
transporter, where they can bind to newly synthesized
MHC class I molecules. In contrast, membrane-associated
proteins and endocytosed “exogenous” proteins are mainly
presented by MHC class II molecules for recognition by
CD4
 
1
 
 T cells. However, the division of the endogenous
and exogenous pathway is not absolute. 25 years ago, it was
recognized that immunization with cells lacking host MHC
alleles, but bearing foreign minor histocompatibility anti-
gens, leads to minor specific CD8
 
1
 
 T cell activation that is
restricted to the host MHC allele (1, 2). This suggested that
host APCs can process exogenous cell-associated antigens
and present them in the context of MHC class I molecules,
a process termed cross-priming or cross-presentation. Since
then, cross-priming has been shown to be important in ini-
tiating MHC class I–restricted responses to tumors, periph-
eral self, viral, and bacterial antigens (3–6). This indicates
that cross-presentation is a general mechanism for the in-
duction of T cells specific for antigens not expressed by
APCs themselves and is involved in a variety of T cell re-
sponses (7). In addition to T cell activation, cross-presenta-
tion has been shown to induce T cell tolerance (8, 9).
Bone marrow chimera studies demonstrated that the
ability to cross-present cell-associated antigens is restricted
to bone marrow–derived APCs (4, 10). Several groups
have investigated the role of macrophages and dendritic
cells (DCs) in presenting exogenously derived antigens in
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MHC class I in vitro (for a review, see reference 7). Exog-
enous antigens in the form of soluble proteins, particulate
antigens, and cell-associated antigens derived from apop-
totic or necrotic cells have been shown to be taken up,
processed, and presented to CD8
 
1
 
 T cells by both cell
types (11–17). Other reports have indicated that cross-pre-
sentation is a specific property of DCs (18–20). However,
which bone marrow–derived APC is involved in MHC
class I–restricted presentation of exogenous antigens in vivo
has not been examined.
DCs comprise populations of cells with heterogeneous
phenotypes (21, 22). Murine splenic DCs can be divided
into two subsets, both of which express high levels of
CD11c. One DC population is further characterized by
high expression of the myeloid marker CD11b and by
absence of expression of CD8
 
a
 
 and DEC-205, whereas
the other is CD11b
 
low
 
CD8
 
a
 
1
 
DEC-205
 
1 
 
(23–27). The
CD8
 
2
 
CD11b
 
high
 
 DCs can be further divided into a CD4
 
1
 
and CD4
 
2
 
 population (28). Some evidence suggests that
the CD8
 
1 
 
and CD8
 
2
 
 DC subsets belong to different lin-
eages. Several transcription factor knockout and mutant
mice exhibited differential effects on the development of
each subset in vivo (29–32). In addition, CD8
 
1 
 
DCs were
shown to be derived from a thymic progenitor that could
not generate myeloid cells, whereas CD8
 
2 
 
DCs can be
grown from bone marrow using GM-CSF (33–35). There-
fore, CD8
 
1 
 
DCs are thought to relate to the lymphoid lin-
eage, whereas CD8
 
2
 
 DCs are considered myeloid related.
For convenience, in this paper we will use the terms lym-
phoid DC and myeloid DC to describe the CD8
 
1 
 
and
CD8
 
2
 
 DC subsets.
In addition to phenotypic differences, the lymphoid and
myeloid DCs reside in different areas of the spleen.
Whereas lymphoid DCs are localized in the T cell–rich ar-
eas of the periarteriolar lymphatic sheaths (PALS), myeloid
DCs can be found in the marginal zone (21, 36). Func-
tional distinctions between lymphoid and myeloid DCs
have also been reported. Initial in vitro studies indicated
that lymphoid DCs could suppress T cell responses by caus-
ing apoptosis of CD4
 
1
 
 T cells and by limiting IL-2 produc-
tion by CD8
 
1
 
 T cells, whereas myeloid DCs were shown
to be strong stimulators of primary T cell responses (37,
38). These findings led to the suggestion that myeloid and
lymphoid DCs function as T cell stimulators and tolerizers,
respectively. However, in a recent study, peptide-coated
DCs of both subsets were shown to induce strong CD8
 
1
 
 T
cell responses, indicating no inherent tolerizing function
for lymphoid DCs (39). Both DC subsets do appear to dif-
fer in their ability to activate CD4
 
1
 
 cells, as myeloid DCs
preferentially stimulate Th2 responses, whereas lymphoid
DCs preferentially induce Th1 responses (40–42). The role
of both DC subsets in cross-priming of CD8
 
1
 
 T cells in
vivo has not been investigated.
To determine the cell types responsible for cross-priming
in vivo, we primed C57BL/6 (B6) mice with irradiated,
 
b
 
2-microglobulin
 
2
 
/
 
2
 
 (
 
b
 
2m
 
2
 
/
 
2
 
) splenocytes loaded with
OVA in their cytoplasm. Such 
 
b
 
2m
 
2
 
/
 
2
 
 splenocytes are un-
able to present the OVA epitope in association with MHC
 
class I molecules, but they elicit, when injected in B6 mice,
OVA-specific, MHC class I–restricted CTL responses. We
show that host splenic DCs take up and present cell-associ-
ated OVA to CD8
 
1
 
 T cells. Analysis of the OVA-present-
ing DCs indicated that only lymphoid DCs, and not my-
eloid DCs, cross-present antigens in vivo. This result points
to an important and distinct role for lymphoid DCs in the
generation of CD8 T cell responses directed towards cell-
associated antigens.
 
Materials and Methods
 
Mice.
 
b
 
2m
 
2
 
/
 
2
 
 and B6 mice were purchased from Taconic
Farms. OT-I recombination-activating gene (RAG)2
 
2
 
/
 
2
 
 and
Thy1.1
 
1
 
 OT-I mice were bred in our specific pathogen-free fa-
cility and have a transgenic V
 
a
 
2V
 
b
 
5 TCR specific for the
OVA
 
257–264
 
 epitope in the context of H2-K
 
b
 
 (43).
 
Antibodies.
 
CD11c-, CD11b-, CD8
 
a
 
-, CD8
 
b
 
-, K
 
b
 
/D
 
b
 
-, and
I-A
 
b
 
–specific antibodies were purchased from BD PharMingen.
Biotinylated DEC-205–specific antibodies were a gift from A.
Rudensky (University of Washington, Seattle, WA). Flow cy-
tometry was conducted on a FACSCalibur™ and analyzed using
CELLQuest™ software (Becton Dickinson). Cell sorting was
performed in HBSS with 25 mM Hepes using a FACS Vantage™
(Becton Dickinson).
 
Cross-priming with OVA-loaded 
 
b
 
2m
 
2
 
/
 
2
 
 Cells.
 
Single cell sus-
pensions were prepared in serum-free medium from spleen and
cervical, axillary, brachial, inguinal, and mesenteric lymph nodes
from female 
 
b
 
2m
 
2
 
/
 
2
 
 mice. Cells were loaded with OVA by os-
motic shock as described previously (44). In short, 
 
z
 
15 
 
3 
 
10
 
7
 
cells were incubated in 1 ml of hypertonic medium (0.5 M su-
crose, 10% wt/vol polyethylene glycol 1000, and 10 mM Hepes
in RPMI 1640, pH 7.2) containing 10 mg/ml OVA (Calbio-
chem) for 10 min at 37
 
8
 
C. 13 ml of prewarmed hypotonic me-
dium (40% H
 
2
 
O, 60% RPMI 1640) was added and the cells were
incubated for an additional 2 min at 37
 
8
 
C. The cells were centri-
fuged, washed twice with cold PBS, and irradiated (1,350 rads).
20–35 
 
3
 
 10
 
6
 
 OVA-loaded cells were injected in 200 
 
m
 
l of PBS
into the tail vein. In one experiment, 
 
b
 
2m
 
2
 
/
 
2
 
 cells were shocked
with both OVA and yellow/green fluorescent 0.2 
 
m
 
m beads
(Molecular Probes). The beads were washed two times in PBS
by centrifugation for 10 min at 1,400 rpm and sonication for 10
min. The beads were resuspended to 0.004% (wt/vol) in hyper-
tonic solution containing OVA before shocking. After osmotic
shocking of the cells, free beads were removed by three washes
in PBS.
 
CFSE Labeling of OT-I Cells.
 
OT-I cells from spleen and
lymph nodes were washed twice in PBS containing 0.1% BSA.
To label cells with the intracellular fluorescent dye carboxyfluo-
rescein diacetate succinimidyl ester (CFSE; Molecular Probes) the
cells were resuspended at 5 
 
3
 
 10
 
7
 
 cells/ml in PBS/0.1% BSA
with 10 
 
m
 
M CFSE for 10 min at 37
 
8
 
C. Cells were washed twice
with cold RPMI 1640/10% FCS (RP10) followed by two
washes in PBS. 10
 
6
 
 CD8
 
1
 
V
 
a
 
2
 
1
 
CFSE
 
1
 
 OT-I cells in 200 
 
m
 
l of
PBS were injected into the tail vein.
 
Low Density Cell Preparation.
 
14 h after injection with irradi-
ated OVA-loaded 
 
b
 
2m
 
2
 
/
 
2
 
 cells, spleens of 5–35 mice were cut
into grain size pieces and incubated in 1 ml per spleen of 1 mg/
ml collagenase/dispase (Sigma-Aldrich) and 50 
 
m
 
g/ml DNase I
(Boehringer) in PBS with continuous stirring at 37
 
8
 
C for 30 min
or until digested. EDTA was added to a 10 mM final concentra-
tion, and the cell suspension was incubated for an additional 5 
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min at room temperature. RP10/10 mM EDTA/20 mM Hepes
(RP10/HE) was added and the cells were pelleted. Red blood
cells were lysed with ACK lysis buffer. Cells were washed once
with RP10 and the cells were resuspended in 10 ml/5 spleens of
RP10/HE. Undigested material was removed by filtration
through a wire mesh screen and the cell suspension was loaded
on 14.5% Accudenz (Accurate Chemical & Scientific Corpora-
tion) gradients in RP10/HE and centrifuged at 530 
 
g
 
 for 20 min
at room temperature (25). The low density fraction was recov-
ered and washed once in RP10/HE and resuspended in RP10.
 
Magnetic Bead Depletion.
 
5 
 
3
 
 10
 
6
 
 low density cells were incu-
bated with 300 
 
m
 
l 2.4G2 supernatant (anti-Fc receptor) for 15
min on ice. Cells were then incubated with 200–250 
 
m
 
l of bio-
tinylated antibody specific for CD11c, CD11b, CD8
 
a
 
, or CD8
 
b
 
in PBS/0.1% BSA for 30 min at 4
 
8
 
C under slow rotation. Deple-
tion of antibody-bound cells with streptavidin-coated magnetic
beads (Dynal) was performed in PBS/0.1% BSA according to the
manufacturer’s instructions.
 
Proliferation Assay.
 
To detect OVA cross-priming, different
DC preparations from injected mice were used as stimulators for
naive OT-I cells in a [
 
3
 
H]thymidine incorporation assay. Indi-
cated numbers of irradiated (2,250 rads) DCs were incubated
with 10
 
5
 
 OT-I RAG2
 
2
 
/
 
2
 
 cells in flat-bottomed plates in 200 ml
RP10. As a positive control, stimulator cells were coated with 1
mM OVA257–264 peptide for 1 h and washed three times. After
48 h, the plates were pulsed for 16 h with 1 mCi/well of [3H]thy-
midine and harvested.
Results
Cross-presentation to CD81 T Cells In Vivo. To study
the MHC class I–restricted cross-presentation of cell-asso-
ciated antigens, we injected B6 mice intravenously with
b2m2/2 cells that had been osmotically loaded with OVA.
As expected, the injected cells are efficiently taken up and
processed for MHC class I presentation by host APCs. This
is demonstrated by the proliferative response of adoptively
transferred, CFSE-labeled H2-Kb–restricted, OVA-spe-
cific TCR transgenic OT-I cells that serve as an indicator
for efficient presentation in vivo. 3 d after priming, the
transferred OT-I cells had divided up to seven times, as re-
vealed by the sequential loss of CFSE intensity (Fig. 1 A).
In contrast, OT-I cells did not proliferate in mice that did
not receive OVA-loaded cells (Fig. 1 B).
Low Density Cells Cross-present Cell-associated Antigens in a
TAP-dependent Manner. Because we immunized mice via
the intravenous route, we focussed our attention on the
Figure 1. CD81 T cell proliferation in vivo after priming with OVA-
loaded b2m2/2 (b2m0/0) cells. Thy1.11 CFSE-labeled OT-I cells were
transferred into B6 mice. 3 d later, mice were primed by injection with
irradiated OVA-loaded b2m2/2 cells. Spleen cells were isolated 3 d after
priming and stained for Thy1.1, Va2, and CD8. (A) CFSE profile of
Thy1.11Va21CD81 OT-I cells from mice primed with OVA-loaded
b2m2/2 cells. (B) The same profile from a mouse that received no OVA-
loaded b2m2/2 cells.
Figure 2. Low density spleen cells cross-present OVA in a TAP-
dependent fashion. B6 (A) and TAP2/2 (TAP0/0) mice (B) were primed
with OVA- or BSA-loaded b2m2/2 cells. Low density spleen cells were
isolated 14 h after injection and analyzed for their ability to stimulate OT-I
cells in vitro. As indicated, the different bars represent titered numbers of
low density cells added per well. Error bars indicate SEM of triplicate
wells. The stimulatory capacity of low density cells after pulsing with
OVA257–264 peptide in vitro is shown in the insets.1688 CD81 Dendritic Cells Cross-prime CTLs In Vivo
spleen as the source of the cross-presenting APC. To iden-
tify the cross-presenting cell, we isolated low density spleen
cells from mice 14 h after injection of b2m2/2 cells loaded
with BSA or OVA. These cells were then used to stimulate
naive OT-I cells in an in vitro proliferation assay in the ab-
sence of additional antigen. The low density cell prepara-
tion was enriched for DCs and generally contained ,1%
Db/Kb-negative cells, indicating the paucity of injected
OVA-loaded  b2m2/2 cells (data not shown). Low density
spleen cells from mice injected with OVA/b2m2/2 cells,
but not from mice injected with BSA/b2m2/2 cells, were
able to stimulate naive OT-I cells in vitro (Fig. 2 A). Low
density cells from both types of mice were able to stimulate
proliferation after peptide pulsing in vitro (Fig. 2 A, inset).
Processing of exogenous antigens can involve an endo-
some to cytosol pathway in which the endocytosed antigen
is transported to the cytosol and further processed and pre-
sented via the “classical” endogenous pathway (20). The
TAP transporter is essential in this pathway, in that it trans-
ports peptides that are generated by the proteasome from
the cytosol to the endoplasmic reticulum where they bind
nascent MHC class I molecules. TAP has been shown to be
essential for cross-priming MHC class I–restricted responses
in vivo (3, 45). Alternatively, a TAP-independent pathway
of class I MHC cross-presentation has also been described
(7, 46, 47). To determine which pathway is used for the
cross-presentation of cell-associated antigens in vivo, BSA-
or OVA-loaded b2m2/2 cells were injected into TAP2/2
mice and low density spleen cells from these mice were
evaluated for their capacity to stimulate OT-I in vitro. Low
density cells from TAP2/2 mice could not stimulate OT-I
cells, indicating that the endosome to cytosol pathway is
employed for cross-presentation of cell-associated antigens
in this system (Fig. 2 B). This result also shows that con-
taminating APCs in the OT-I cell preparation did not
contribute to the proliferation in vitro. The various low
density spleen cell preparations did not differ in their pre-
sentation capacity, as exogenous OVA peptide pulsing of
all preparations showed similarly strong stimulatory capac-
ity for OT-I T cells.
Only Lymphoid DCs Cross-present OVA Antigen to CD81
T Cells. To investigate further which cell population
within the low density cell preparation was responsible for
cross-presentation, we first evaluated which cell types were
present. Flow cytometric analysis of the low density cells
revealed four cell populations as defined by CD11c and
CD11b staining (Fig. 3). A population of CD11c2CD11b2
cells that consisted mainly of T and B cells made up 10–
20% of the preparation. Besides these residual T and B
cells, a population of CD11c2 and CD11b2 cells were de-
tected that were autofluorescent in the FL-1, FL-2, and
FL-3 channels, which could be misinterpreted as low level
Figure 3. Phenotypic analysis
of low density cell preparation.
Low density spleen cell prepara-
tions were isolated from B6 mice
14 h after priming with OVA-
loaded b2m2/2 cells. The cells
were stained for CD11c,
CD11b, and the indicated third
reagent, and analyzed by
FACS®. Gated myeloid DCs
(CD11bhighCD11chigh) and lym-
phoid DCs (CD11blow
CD11chigh) were further ana-
lyzed for CD8a, DEC-205,
CD4, and MHC class II expres-
sion. MyDC, myeloid DCs;
LyDC, lymphoid DCs; AFC,
autofluorescent cells, mostly
macrophages.1689 den Haan et al.
expression of CD11c and CD11b. The autofluorescent
cells expressed MHC class I, heterogeneous levels of MHC
class II, and low levels of the macrophage marker F4/80,
but no CD4, CD8a, or DEC205 (data not shown). This
phenotype is consistent with recently described autofluo-
rescent cells present in DC cell preparations that were iden-
tified as macrophages (28). Our low density cell preparation
contained z30–40% myeloid and 10–30% lymphoid DCs,
both expressing high levels of CD11c but different levels of
CD11b (Fig. 3). Analysis of the myeloid and lymphoid DC
subsets revealed high MHC class II expression by both sub-
sets, high CD8a and DEC205 expression by the lymphoid
DCs, and heterogenous CD4 and low DEC-205 expres-
sion by the myeloid DC subset, consistent with previously
published studies (25, 26, 28).
We asked whether cross-presentation is a specific charac-
teristic of DCs and, if so, whether it is a feature of a partic-
ular DC subset. Therefore, we depleted the low density
cell preparation from OVA/b2m2/2-primed mice of spe-
cific cell subsets using antibodies and magnetic beads and
the remaining cells were evaluated for their capacity to
stimulate OT-I cells in vitro (Fig. 4). Depletion of CD11c1
cells in the DC preparation resulted in the loss of both the
myeloid and lymphoid DC subsets (66% CD11c1 cells
were present before depletion, and 8% after depletion, data
not shown). The remaining cells consisted of autofluores-
cent and CD11c2CD11b2 cells and showed almost no
OVA presentation. These results demonstrate that cross-
presentation of cell-associated OVA is mediated entirely by
CD11c1 DCs. Depletion of F4/801 cells resulted in no loss
of activity (data not shown). Therefore, CD11c2 macro-
phages do not seem to play an important in vivo role in
cross-presenting cell-associated antigens.
Depletion of CD11b1 cells specifically removed myeloid
DC (38% predepletion to 9% postdepletion) and concomi-
tantly increased the percentage of lymphoid DCs (26% pre-
depletion to 48% postdepletion). This resulted in a higher
stimulatory activity of the DC preparation (Fig. 4). To spe-
cifically deplete for lymphoid DCs, we used anti-CD8a
antibodies. However, this depletion of the lymphoid DC
subset was only z50% complete (22% predepletion to 13%
postdepletion) with the preferential loss of the CD8ahigh-
expressing lymphoid DCs (data not shown). The specific
depletion of CD8ahigh lymphoid DCs resulted in significant
loss of stimulatory activity (Fig. 4). Finally, depletion for
CD8b1 cells did not lead to a significant change in num-
bers of the different subsets or in OVA cross-presenting ac-
tivity. These results suggest that the lymphoid DC was the
main cross-presenting APC.
To confirm our findings, we isolated low density cells
from mice injected previously with OVA-loaded b2m2/2
cells and sorted myeloid and lymphoid DCs on the basis of
their CD11b and CD11c expression. Sorting for myeloid
and lymphoid DC populations resulted in 87 and 84% pure
populations, respectively (Fig. 5 A). The sorted DC subsets
were used as APCs for OT-I in an in vitro proliferation as-
say. Whereas sorted myeloid DCs lacked stimulatory ca-
pacity, sorted lymphoid DCs had stimulatory activity that
was stronger than that of the starting DC preparation (Fig.
5 B). This result clearly demonstrates that only lymphoid
DCs have the ability to cross-present antigen acquired in
vivo from injected b2m2/2 cells.
Lymphoid DCs Rapidly Acquire Antigen In Vivo. It has
been suggested that antigens are transferred from migratory
DCs to DCs in the T cell areas (41, 48, 49). Other studies
clearly indicate a migration of DCs from the marginal zone
where the myeloid DCs are localized into the central T cell
areas of the PALS where lymphoid DCs can be found (50–
52). This could indicate that marginal zone DCs can trans-
fer antigens to the lymphoid DCs or that marginal zone
DCs may mature into lymphoid DCs. Both alternatives
would predict that early after injection of OVA/b2m2/2
cells, the OVA stimulatory capacity would not be restricted
to the lymphoid DC subset. We therefore isolated myeloid
and lymphoid DCs soon after injection of OVA/b2m2/2
cells and evaluated their OT-I stimulatory capacity (Fig. 6).
As early as 2 h after injection, all the OVA stimulatory ac-
tivity was found in the lymphoid DC subset. Unless trans-
fer of antigens between DCs or the maturation of myeloid
DCs into lymphoid DCs is an extremely rapid process, this
result suggests that the lymphoid DCs themselves take up
and present the cell-associated antigens in vivo.
Figure 4. OVA cross-presentation by low density cells depleted of dif-
ferent cell subsets. Low density spleen cells were isolated from B6 mice 14 h
after priming with BSA/b2m2/2 or OVA/b2m2/2 cells. The low density
cells from OVA/b2m2/2-injected mice were depleted of CD11c1,
CD11bhigh, CD8ahigh, and CD8b1 cells by magnetic beads and the de-
pleted populations were tested (A) directly for their presenting activity in
an in vitro OT-I proliferation assay (2 3 105 stimulator cells/well) or (B)
after pulsing with OVA peptide in vitro (2 3 104 cells/well). Error bars
indicate SEM of triplicate wells.1690 CD81 Dendritic Cells Cross-prime CTLs In Vivo
Myeloid DCs Take Up Cell-associated Antigens. The lack
of presentation by myeloid DCs could be explained if they
do not have access to the injected, antigen-bearing cells.
This could either be due to the failure of the injected cells
to home to the marginal zone areas where myeloid DCs
reside, or the myeloid DCs may lack specific surface recep-
tors for the internalization of cell-associated antigen. To
determine whether myeloid DCs take up cell-associated
antigens, b2m2/2 cells were shocked with both OVA and
yellow/green fluorescent beads and injected into B6 mice.
Splenic low density cells were isolated 14 h after injection,
stained for CD11c and CD11b, and analyzed by flow cy-
tometry (Fig. 7 A). Cells containing one or more fluores-
cent beads were detected in the FITC channel. The
CD11c and CD11b FACS® profile of bead-positive cells
clearly shows that in addition to lymphoid DCs, both my-
eloid DCs and autofluorescent macrophages have taken up
beads derived from b2m2/2 cells (Fig. 7 B). This result in-
dicates that the restricted presentation by lymphoid DCs is
not due to restricted uptake of cell-associated antigens.
Only a Small Fraction of Lymphoid DCs Present OVA.
We made two estimates of the fraction of cells within the
isolated low density preparation that could present OVA to
OT-1 after in vivo uptake of antigen. At 14 h after injec-
tion of cells loaded with OVA and fluorescent beads, 0.8%
of the total low density cell preparation was bead-positive,
as determined by FITC fluorescence (Table I). Within the
lymphoid DC subset, which made up 27% of the cells, 1%
were bead-positive. Therefore, only 0.27% of the total low
density cell preparation was estimated to contain and
present OVA to OT-1 cells.
Second, the amount of OT-1 proliferation stimulated by
in vivo–derived low density cells was compared with that
Figure 5. Lymphoid DCs, but not myeloid DCs, cross-
present OVA antigen. Low density cells were isolated
from mice primed previously with OVA- or BSA-loaded
b2m2/2 cells. Myeloid and lymphoid DCs from OVA/
b2m2/2-injected mice were (A) FACS® sorted based on
their differential CD11b/CD11c expression and (B) tested
for their ability to stimulate naive OT-I cells in vitro. The
different bars represent titered numbers of DCs in the
well. The proliferation of OT-I induced by peptide-pulsed
cells is depicted in the inset. One of three experiments
with similar results is shown. Error bars indicate SEM of
triplicate wells. MyDC, myeloid DCs; LyDC, lymphoid
DCs; AFC, autofluorescent cells, mostly macrophages;
n.t., not tested.
Table I. In Vivo Uptake of Cell-associated Beads
Percentage
of total
Percentage
of bead1 cells
in each subset
Low density cell preparation 100 0.8
Myeloid DCs 41 0.6
Lymphoid DCs 27 1.0
Autofluorescent cells 13 1.5
The percentage of different subsets in low density cell preparation and
the percentage of each that contain beads.1691 den Haan et al.
stimulated by a titration of in vitro peptide-pulsed low
density cells. This comparison suggested that 0.32% of lym-
phoid DCs, or 0.06% of low density cells, presented OVA
(average of three experiments, data not shown). This is pre-
sumably an underestimate of the number of OVA-present-
ing cells, as the amount of OVA acquired in vivo is proba-
bly lower than the amount of OVA used for exogenous
peptide pulsing. Together, these experiments suggest that
only z1% of the lymphoid DC subset present OVA in
vitro.
Discussion
Cross-presentation of exogenous antigens in association
with MHC class I molecules has been studied extensively
in vitro. Both macrophages and DCs have been shown to
present peptides derived from soluble and particulate anti-
gens in the context of MHC class I molecules (for a review,
see reference 7). In addition, antigens from apoptotic or
necrotic cells can be processed and presented in MHC class
I by both cell types in vitro (15, 19, 53, 54). In contrast,
there is little information concerning the identity of cross-
presenting cells in vivo. DCs have been shown to present
soluble protein-derived and cell-associated antigens in
MHC class II molecules (48, 51, 55), but the cell that
cross-presents antigens in association with MHC class I
molecules in vivo has remained elusive. In our study, we
have isolated low density spleen cells from in vivo–primed
mice and shown that they present exogenously derived an-
tigens in association with MHC class I in a TAP-dependent
manner. Further analysis of the cross-presenting cells iden-
tified them as CD11c1 DCs. This is the first isolation and
characterization of DCs in the central lymphoid organs that
have taken up cell-associated antigens to present them to
CD81 T cells in vivo.
Further experiments showed that only the lymphoid DC
subset cross-presents cell-associated antigens in MHC class I
molecules in the spleen. The number of actual OVA-pre-
senting cells is very low. We estimated that only 1% of lym-
phoid DCs present OVA to T cells. The lymphoid DC
subset–restricted presentation was evident as early as 2 h af-
ter immunization, which strongly suggests that lymphoid
DCs themselves take up the exogenous cell-associated anti-
gen. Transfer of antigen between different DC subsets, as
had been suggested, is therefore unlikely (41, 48, 49). In
support of the notion of direct uptake of antigen by lym-
phoid DCs, rat DCs containing apoptotic cell remnants
have been found to migrate to the T cell areas of lymph
nodes. These DCs were CD42 and may be the rat equiva-
lent of the mouse lymphoid DCs (56). Our finding that
only lymphoid DCs cross-present cell-associated antigens in
the spleen does not preclude the presence of other types of
APCs with cross-priming function in other tissues. APCs
have been isolated from tumors and islets of Langerhans
that could stimulate CD81 T cells specific for tumor and is-
let antigens, respectively (57–59). One of these studies de-
fined the phenotype of the APCs as macrophage like (57).
Why do only lymphoid and not myeloid DCs cross-
present cell-associated antigens to CD81 T cells? In princi-
ple, it could be the result of differences in the uptake of cell
debris, processing ability, or their T cell stimulatory capac-
ity. We show that, in addition to lymphoid DCs, both au-
Figure 6. MHC class I–restricted cross-presentation is restricted to
lymphoid DCs as early as 2 h after priming. Low density cells were iso-
lated from mice 2 or 14 h after priming with OVA-loaded b2m2/2 cells.
Myeloid and lymphoid DCs were FACS® sorted based on their differen-
tial CD11b/CD11c expression and tested for their ability to stimulate na-
ive OT-I cells in vitro. The different bars represent titered numbers of
DCs in the well. Error bars indicate SEM of triplicate wells. MyDC, my-
eloid DCs; LyDC, lymphoid DCs; n.t., not tested.
Figure 7. Uptake of cell-associated beads by both DC
subsets and autofluorescent macrophages. Low density cells
were isolated from mice 14 h after priming with OVA/
bead-loaded b2m2/2 cells. (A) The cells were stained for
CD11c and CD11b and analyzed by FACS®. MyDC, my-
eloid DCs; LyDC, lymphoid DCs; AFC, autofluorescent
cells, mostly macrophages. (B) CD11c and CD11b profile
of the gated low density cells containing beads.1692 CD81 Dendritic Cells Cross-prime CTLs In Vivo
tofluorescent macrophages and myeloid DCs contain cell-
associated beads. This indicates that uptake of cell-associ-
ated antigen is not restricted to lymphoid DCs. This con-
trasts with the study by Fossum and Rolstad, in which
allogeneic lymphocyte cell debris was found mainly in
lymphoid DCs (60). However, differences in the in vivo
model systems used may explain this discrepancy. Second,
myeloid and lymphoid DCs do not seem to differ in their
capacity to stimulate T cells, as both DC subsets have been
shown to stimulate CD81 T cells efficiently in vitro and in
vivo (39). This leaves differences in antigen processing
pathways between myeloid and lymphoid DCs as the most
likely explanation. A selective transport of internalized an-
tigens to the cytosol has been shown to occur in DCs and
to be absent in macrophages (20). Both bone marrow–
derived DCs and a splenic-derived DC line exhibited this
ability, but ex vivo DCs were not evaluated. Our results
suggest that this endosome to cytosol transport will be lim-
ited to lymphoid DCs.
Cross-presentation of cell-associated antigens to CD81 T
cells has been shown to result in either T cell activation or
tolerance (1, 2, 8–10, 61, 62). In both cases, bone marrow–
derived cells are necessary (8–10). Lymphoid DCs have
been speculated to mediate peripheral tolerance, whereas
myeloid DCs have been suggested to be essential for T cell
stimulation (49, 63). Our studies do not specifically address
the outcome of the DC–T cell interaction, as T cell pro-
liferation is involved in both processes. However, our
method of intravenous immunization with OVA-loaded
cells has repeatedly been shown to lead to T cell activation
and memory (10, 61, 64). Therefore, we are convinced
that we have isolated the APC required for CD81 T cell
cross-priming.
An attractive alternative explanation for the different
outcomes of DC–T cell interaction is offered by several
studies indicating that the activation state of the DCs is an
important factor. DCs involved in cross-priming are acti-
vated via CD40–CD40L interaction provided by CD41 T
cells (64–66). CD81 T cell cross-priming does not occur in
the absence of CD41 T cells, illustrating the crucial role of
CD41 T cells in this process (10). Likewise, CD41 T cells
play an important role in preventing the induction of
CD81 T cell tolerance to self-antigens, as the addition of
antigen-specific CD41 T cells converts CD81 T cell toler-
ance induction into CD81 T cell activation (67). Further-
more, in several other tolerance induction systems, in vivo
CD40 activation resulted in abrogation of tolerance and in
T cell activation (68–71). Taken together, these studies
strongly suggest that the activation state of the DCs is an
important factor in determining the outcome of the DC–T
cell interaction and that lymphoid DCs may be implicated
in both activation and tolerization of antigen-specific
CD81 T cells.
Recent studies suggest different functions for lymphoid
and myeloid DCs in the activation of CD41 T cells, prefer-
entially inducing Th1 and Th2 responses, respectively (40–
42). The capacity of lymphoid DCs to drive Th1 responses
is explained by their production of IL-12 and IFN-g (27,
52, 72). Furthermore, the localization of the different DC
and Th subsets appears to be similar. Th1 cells primarily re-
side in proximity to the lymphoid DCs in the central T cell
zone of the PALS, whereas Th2 cells are found in the outer
PALS near the B cell follicles and the marginal zone where
myeloid DCs are located (73). Differential chemokine re-
ceptor expression patterns in both Th and DC subsets are
essential in establishing this homing pattern (73–76). Our
data add a new role for the lymphoid DCs as the main
stimulator of CD81 T cell responses specific for cell-associ-
ated antigens. This points to an interaction between lym-
phoid DCs, CD81 T cells, and Th1 cells. It remains to be
investigated whether CD81 T cell cross-priming is specifi-
cally associated with and dependent on Th1 responses.
In summary, our data demonstrate that lymphoid DCs
play a key role in cross-presentation of cell-associated anti-
gens to CD81 T cells in vivo. Because cross-presentation
enables the activation of naive T cells specific for antigens
that are not expressed by the APCs themselves, we envis-
age that lymphoid DCs will be essential for the induction
of a large spectrum of CD81 T cell responses.
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